Polymeric nanoparticle technologies for oral drug delivery.
暂无分享,去创建一个
[1] Robert Langer,et al. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. , 2013, ACS nano.
[2] R. N. Brogden,et al. Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. , 1987, Drugs.
[3] R. Doyle,et al. Traveling the Vitamin B12 Pathway: Oral Delivery of Protein and Peptide Drugs , 2009 .
[4] P. Bjorkman,et al. The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. , 1993, Biochemistry.
[5] M. Mullendore,et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities , 2008, Molecular Cancer Therapeutics.
[6] K. Knopf,et al. Estimating Patient Time Costs Associated With Colorectal Cancer Care , 2005, Medical care.
[7] Didier Merlin,et al. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. , 2010, Nature materials.
[8] N. Mantis,et al. A Population of Langerin-Positive Dendritic Cells in Murine Peyer's Patches Involved in Sampling β-Glucan Microparticles , 2014, PloS one.
[9] T. Yen,et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. , 2012, Molecular pharmaceutics.
[10] B. Fleshler,et al. Physiology of the Gastrointestinal Tract , 1969 .
[11] E. Mathiowitz,et al. Oral delivery of proteins by biodegradable nanoparticles. , 2013, Advanced drug delivery reviews.
[12] D. Roopenian,et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. , 2004, Immunity.
[13] K. Badizadegan,et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. , 1999, The Journal of clinical investigation.
[14] J. Smart. The basics and underlying mechanisms of mucoadhesion. , 2005, Advanced drug delivery reviews.
[15] Yun-Seok Rhee,et al. Nanomedicine in pulmonary delivery , 2009, International journal of nanomedicine.
[16] Jinho Park,et al. Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy , 2012, Theranostics.
[17] Y. Kawashima,et al. Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.
[18] N. Peppas,et al. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[19] Hsing-Wen Sung,et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. , 2011, Biomaterials.
[20] Laura M Ensign,et al. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.
[21] G. M. Gray,et al. Protein digestion and absorption. , 1971, Gastroenterology.
[22] C. V. Van Itallie,et al. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[23] Yves-Jacques Schneider,et al. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[24] V. Ganapathy. Protein Digestion and Absorption , 2012 .
[25] H. Fessi,et al. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. , 2005, Critical reviews in therapeutic drug carrier systems.
[26] M. Postma,et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. , 2004, Clinical therapeutics.
[27] T. Kararli. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.
[28] E. Allémann,et al. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues , 2005, AAPS PharmSciTech.
[29] P. Lowe,et al. Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats , 1994, The Journal of pharmacy and pharmacology.
[30] Zhen Gu,et al. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. , 2014, Chemical Society reviews.
[31] Y. Talmon,et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption , 2013, Proceedings of the National Academy of Sciences.
[32] Esther Jacobowitz Israel,et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells , 1997, Immunology.
[33] P. Gorden,et al. The use of U-500 in patients with extreme insulin resistance. , 2005, Diabetes care.
[34] Pedro M. Valencia,et al. Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .
[35] T. Macdonald,et al. Immunity, Inflammation, and Allergy in the Gut , 2005, Science.
[36] E. Kaltenthaler,et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer , 2006, British Journal of Cancer.
[37] M. Ranson,et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Yoshinori Onuki,et al. Current challenges in non-invasive insulin delivery systems: a comparative review. , 2007, Advanced drug delivery reviews.
[39] Saurabh Aggarwal,et al. What's fueling the biotech engine—2011 to 2012 , 2012, Nature Biotechnology.
[40] Yves-Jacques Schneider,et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[41] R. James,et al. 271 Savings in staff time as a result of switching from De Gramont to oral capecitabine for patients with advance colorectal cancer , 2003 .
[42] Hsing-Wen Sung,et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. , 2013, Advanced drug delivery reviews.
[43] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[44] E. Warner,et al. Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] H. Takeuchi,et al. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[46] R. Langer,et al. Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery , 2013, Science Translational Medicine.
[47] P Couvreur,et al. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. , 1997, Journal of pharmaceutical sciences.
[48] P. Diwan,et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[49] Hsing-Wen Sung,et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. , 2009, Biomaterials.
[50] Thomas R. Tice,et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .
[51] C. Sasakawa,et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[52] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[53] Hsing-Wen Sung,et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. , 2011, Biomaterials.
[54] C. Alexander,et al. Nanoparticle transport in epithelial cells: pathway switching through bioconjugation. , 2013, Small.
[55] G. Cartenì,et al. Cost Analysis of Capecitabine vs 5-Fluorouracil-Based Treatment for Metastatic Colorectal Cancer Patients , 2010, Journal of chemotherapy.
[56] A. Hubbard,et al. Transcytosis: crossing cellular barriers. , 2003, Physiological reviews.
[57] Qiuhao Qu,et al. Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. , 2013, Angewandte Chemie.
[58] L. Holm,et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[59] Robert Langer,et al. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.
[60] Sergio Grinstein,et al. Sensors and regulators of intracellular pH , 2010, Nature Reviews Molecular Cell Biology.
[61] Y. Schneider,et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[62] Robert Langer,et al. Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.
[63] P. Diwan,et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[64] G. Peters,et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.
[65] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[66] Saurabh Aggarwal,et al. What's fueling the biotech engine? , 2007, Nature Biotechnology.
[67] Carino,et al. Oral insulin delivery. , 1999, Advanced drug delivery reviews.
[68] R. Panchagnula,et al. Peroral route: an opportunity for protein and peptide drug delivery. , 2001, Chemical reviews.
[69] B. Hirst,et al. Exploiting M cells for drug and vaccine delivery. , 2001, Advanced drug delivery reviews.
[70] David Lalezari,et al. Gastrointestinal pH profile in subjects with irritable bowel syndrome , 2012, Annals of gastroenterology.
[71] David J Brayden,et al. Oral vaccination in man using antigens in particles: current status. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[72] D. Cremaschi,et al. Confocal analysis of fluorescent bead uptake by mouse Peyer's patch follicle‐associated M cells , 1992, Experimental physiology.
[73] Celinda M Gourd,et al. Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. , 2008, International journal of pharmaceutics.